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Abstract
Epidemiological evidence indicates a significant association
between vitamin D deficiency and an increased incidence of auto-
immune diseases. The presence of vitamin D receptors in the cells
of the immune system and the fact that several of these cells
produce the vitamin D hormone suggested that vitamin D could
have immunoregulatory properties, and now potent immuno-
mudulatory activities on dendritic cells, Th1 and Th17 cells, as well
as B cells have been confirmed. Patients with undifferentiated
connective tissue disease also show vitamin D deficiency and,
interestingly, patients who progress into connective tissue
diseases have lower vitamin D levels than those who remain in the
undifferentiated connective tissue disease stage.
Vitamin D deficiency and autoimmune diseases
The recent study by Zold and colleagues [1] reports that a
seasonal variance in levels of 25(OH)D3 was identified in
patients with undifferentiated connective tissue disease (UCTD)
and showed that these levels were, in any case, significantly
lower than in controls during the corresponding seasons. The
results showed also that more severe vitamin D deficiency in
UCTD patients may play a role in the subsequent progress
into well-defined connective tissue diseases (CTDs).
Epidemiological evidence indicates a significant association
between vitamin D deficiency and an increased incidence of
autoimmune diseases [2]. Serum levels of vitamin D have
been found to be significantly lower in patients with systemic
lupus erythematosus (SLE) and type-1 diabetes mellitus than
in the healthy population [3]. In addition, it was also found
that lower levels of vitamin D were associated with higher
disease activity in rheumatoid arthritis [4]. An inverse
correlation has been described between the supplementation
of vitamin D and the development of type-1 diabetes mellitus
and multiple sclerosis [5].
Low serum levels of vitamin D3 might be partially related,
among other factors, to prolonged daily darkness (reduced
activation of pre-vitamin D by ultraviolet B sunlight), different
genetic backgrounds (that is, vitamin D receptor poly-
morphism) and nutritional factors, and could explain the
latitude-related prevalence of autoimmune diseases such as
rheumatoid arthritis (RA) when considering the potential
immunosuppressive roles of vitamin D [2].
Vitamin D or hormone D?
The term vitamin D is, unfortunately, an imprecise term,
referring to one or more members of a group of steroid
molecules (seco-steroids). The A, B, C, and D ring structure
is derived from the cyclopentanoperhydrophenanthrene ring
structure of steroids. In particular, seco-steroids are those in
which one of the rings has been broken [2].
Vitamin D, also known as cholecalciferol, is mainly generated
in the skin of animals when one of the rings of the precursor
molecule 7-dehydrocholesterol has been broken by ultraviolet
B light (UV-B, sun light). Vitamin D (or hormone D) is thus not
a true vitamin, because individuals with adequate exposure to
sunlight do not require dietary supplementation. Although
vitamin D is consumed in food, dietary intake alone is often
insufficient, supplying only 20% of the body’s requirements
[2]. Finally, the liver and kidney help convert vitamin D to its
active hormone forms (vitamin D3 hormone).
There is increasing evidence that steroid hormones (vitamins
D2 and D3) derived from vitamin D act through classic
nuclear receptors (nuclear vitamin D receptors (VDRs)), as
well as specific binding sites on the plasma membrane of
target cells that are coupled to signal transduction systems.
Clarification of the physiological role of endogenous VDR
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agonists in the regulation of autoimmune responses will
support the pharmacological VDR agonists for use in the clinic
[6]. The antiproliferative, prodifferentiative, immunomodulatory
and anti-inflammatory properties of synthetic VDR agonists
could be exploited to treat a variety of autoimmune rheumatic
diseases.
Vitamin D3 produces biological responses as a consequence
of its metabolism into 1α,25(OH)2-vitamin D3 (1,25(OH)2D3)
and 24R,25(OH)2-vitamin D3. The metabolic production of
these two seco-steroids and their generation of a plethora of
biological actions that are attributable to the parent vitamin
D3 are orchestrated via the integrated operation of the
hormone D endocrine system [6]. This system is very similar
in its organization to that of classic endocrine systems and is
characterized by an endocrine gland (the kidney, the source
of the two steroid hormones), target cells that possess
receptors for the steroid hormones, and a feed-back loop
involving changes in serum calcium that alter the secretion of
parathyroid hormone (a stimulator of the renal 1-hydroxylase),
which modulates the output of the D steroid by the kidney [7].
Vitamin D hormone and the immune response
In recent years, the discovery of the VDR in the cells of the
immune system and the fact that several of these cells
produce vitamin D hormone suggested that vitamin D could
have immunoregulatory properties. VDR agonists seem
primarily to inhibit dendritic cell differentiation, and pathogenic
pro-inflammatory T cells, such as Th1 and Th17 cells, and,
under appropriate conditions, they seem to promote a
deviation to the Th2 pathway [2]. In addition, two types of cells
are induced by 1,25(OH)2D3, the T regulatory cells (Tregs)
and the natural killer T cells; induction of these regulatory cells
and direct inhibition of Th1 cells are the mechanisms by which
1,25(OH)2D3 suppresses experimental autoimmunity [8].
Clearly, topical hormone D analogs are efficient in modulating
skin immune response in psoriasis [9]. In addition, vitamin D
may play an important role in the maintenance of B cell
homeostasis and the correction of vitamin D deficiency may
be useful in the treatment of B cell-mediated autoimmune
rheumatic disorders such as SLE [10]. The hormone D
immunomodulatory and anti-inflammatory activities might be
particularly efficient in RA patients and support a therapeutic
role of 1,25(OH)2D3 in such disease.
Conclusion
The new study by Zold and colleagues reporting that, during
the average 2.3 year follow-up period, 21.7% of patients with
UCTD and a deficiency of vitamin D metabolites (hormone D)
further developed well established autoimmune CTD is of
great interest [1]. Patients who progressed into CTDs had
lower vitamin D levels than those who remained in the UCTD
stage and UCTD most frequently progressed into RA, SLE,
Sjögren’s syndrome and mixed connective tissue disease [1].
Therefore, vitamin D hormone deficiency is also confirmed in
UCTD and might represent a new possible risk factor for the
progression into well defined autoimmune rheumatic diseases.
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